Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 18/20 | 0.55 |
| ▸ | CCR6 | P51684 | 1/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261140 | 0.85 | CXCR2 (0.67) | CXCR2CCR6CXCR1 | |
| SCHEMBL12573300 | 0.85 | GAA (0.64) | CXCR2CCR6CXCR1GAA | |
| SCHEMBL16144445 | 0.81 | CXCR2 (0.58) | CXCR2CCR6CXCR1 | |
| SCHEMBL12573353 | 0.81 | CXCR2 (0.54) | CXCR2CCR6CXCR1 | |
| SCHEMBL16164031 | 0.80 | CXCR2 (0.50) | CXCR2CXCR1 | |
| SCHEMBL14865060 | 0.80 | MEN1 (0.64) | CXCR2CXCR1 | |
| SCHEMBL14896217 | 0.80 | CXCR2 (0.62) | CXCR2CCR6CXCR1 | |
| SCHEMBL14904762 | 0.80 | CXCR2 (0.53) | CXCR2CCR6CXCR1 | |
| SCHEMBL14894994 | 0.80 | CXCR2 (0.54) | CXCR2CCR6CXCR1 | |
| SCHEMBL14904751 | 0.78 | CXCR2 (0.55) | CXCR2CCR6CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519168-B2 | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds | MERCK SHARP & DOHME CORP. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110160469-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160469-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | CCL2, CCR1, CXCR1 | CXCR2 5/4885CCR6 20/4885CXCR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.